Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rVSV-Nipah vaccine
- Development stage
- Unknown
- Lead developer
- Public Health Vaccines
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The rVSV-Nipah vaccine is a live-attenuated, recombinant vesicular stomatitis virus (rVSV) vector-based vaccine designed for the prevention of Nipah virus infection. Developed by Public Health Vaccines (PHV) in collaboration with Crozet BioPharma and supported by the Coalition for Epidemic Preparedness Innovations (CEPI), the vaccine utilizes a replication-competent VSV platform. In this construct, the native glycoprotein (G) of the vesicular stomatitis virus is replaced with the glycoprotein (G) of the Nipah virus. This allows the vector to express the Nipah antigen upon administration, eliciting a robust immune response including neutralizing antibodies and cellular immunity. The platform is similar to the one used for the licensed Ebola vaccine, Ervebo, and the Nipah candidate is currently in Phase 1 clinical development.
- Other names
- PHV Nipah vaccinerVSV-ΔG-NiV-G vaccinerecombinant vesicular stomatitis virus-Nipah vaccine
02
Targets
NiV-G (Nipah virus attachment glycoprotein)
Beyond the preview
Go deeper on rVSV-Nipah vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rVSV-Nipah vaccine.